Harvard Bioscience (NASDAQ:HBIO) reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $28.8 million versus the consensus estimate of $28.77 million.
Harvard Bioscience (NASDAQ:HBIO) reported Q1 EPS of $0.04, $0.01 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $28.8 million versus the consensus estimate of $28.77 million.